Jubilant Life Sciences gets USFDA nod for hypertension drug
New Delhi: Drug firm Jubilant Life Sciences said it has received final approval from the US health regulator for olmesartan medoxomil tablets, used in the treatment of hypertension.
In a BSE filing, the company said it has received abbreviated new drug application (ANDA) final approval for olmesartan medoxomil tablets - 5 mg, 20 mg, and 40 mg.
The approved product is the generic version of Benicar of Daiichi Sankyo, which is used for the treatment of hypertension.
As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for oral solids filed in the US, of which 49 have been approved.
Shares of the company were trading at Rs 827.50, up 4.72 per cent on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd